

# Tyler D Bold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1130073/publications.pdf>

Version: 2024-02-01

17  
papers

425  
citations

1040056

9  
h-index

1058476

14  
g-index

19  
all docs

19  
docs citations

19  
times ranked

965  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. <i>Journal of Immunology</i> , 2021, 207, 376-379.   | 0.8  | 124       |
| 2  | Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. <i>PLoS Pathogens</i> , 2021, 17, e1009292.                                | 4.7  | 76        |
| 3  | A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EClinicalMedicine</i> , 2021, 37, 100957.  | 7.1  | 56        |
| 4  | Cutting Edge: Mouse SARS-CoV-2 Epitope Reveals Infection and Vaccine-Elicited CD8 T Cell Responses. <i>Journal of Immunology</i> , 2021, 206, 931-935.  | 0.8  | 36        |
| 5  | <scp>SARS-CoV-2</scp> neutralization and serology testing of <scp>COVID-19</scp> convalescent plasma from donors with nonsevere disease. <i>Transfusion</i> , 2021, 61, 17-23.                                    | 1.6  | 25        |
| 6  | Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 69, 869-872.   | 5.8  | 22        |
| 7  | Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography. <i>Nature Communications</i> , 2021, 12, 7325.  | 12.8 | 22        |
| 8  | Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA. <i>Clinical Biochemistry</i> , 2021, 90, 15-22.             | 1.9  | 19        |
| 9  | Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. <i>Blood Advances</i> , 2021, 5, 54-60.  | 5.2  | 11        |
| 10 | Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis. <i>Mycoses</i> , 2020, 63, 58-64.   | 4.0  | 9         |
| 11 | Prevalence of Auto-antibodies in Pulmonary Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz114.   | 0.9  | 5         |
| 12 | Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA-vaccinated patients with inflammatory bowel disease. <i>JCI Insight</i> , 2022, 7, .  | 5.0  | 5         |
| 13 | Reply to Singh. <i>Clinical Infectious Diseases</i> , 2020, 71, 471-472.  | 5.8  | 3         |
| 14 | Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial. <i>Journal of Infectious Diseases</i> , 2021, 223, 1339-1344. | 4.0  | 2         |
| 15 | A eulogy for Dr Francisco Miguel Marty Forero. <i>Transplant Infectious Disease</i> , 2021, 23, e13645.   | 1.7  | 0         |
| 16 | Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. <i>Open Forum Infectious Diseases</i> , 0, , .  | 0.9  | 0         |
| 17 | A New Strategy to Prevent "Deja vu" , 2022, 1, .  |      | 0         |